Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05206175 · ClinicalTrials.gov registry record · NA

Demonstration of a Digital Care Program for Methamphetamine Use Disorder

A NA study of Methamphetamine Abuse, sponsored by Affect Therapeutics.

Completed
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT05206175 is a NA study of Methamphetamine Abuse that has completed, run by Affect Therapeutics. The registered enrollment target is 100 participants, below the 202-participant average among 15 other Methamphetamine Abuse trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05206175, a NA study of Methamphetamine Abuse, has completed, sponsored by Affect Therapeutics.

COMPLETED
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This Phase I Small Business Innovation Research (SBIR) project will examine the technical merit and real-world feasibility of the Affect smartphone application ("app") as the core component of the Affect digital care program for treatment of methamphetamine use disorder (MUD).

Conditions Studied

Interventions

  • OTHER Affect Treatment Program for Methamphetamine Use Disorder

Study Locations (1)

New York

  • Affect Therapeutics - New York

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2022-02-14
Est. Completion 2022-12-31
Phase NA

Sponsor

Affect Therapeutics

2 total trials

What the Registry Record Tells You About NCT05206175

The ClinicalTrials.gov registry entry for NCT05206175 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 15 other Methamphetamine Abuse trials with a reported enrollment target (50% lower). The listed sponsor is Affect Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Methamphetamine Abuse appearing as the primary indexed condition, and to 1 intervention - of which Affect Treatment Program for Methamphetamine Use Disorder is the first listed.

NCT05206175 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05206175 about?

NCT05206175 is a clinical study titled "Demonstration of a Digital Care Program for Methamphetamine Use Disorder". This Phase I Small Business Innovation Research (SBIR) project will examine the technical merit and real-world feasibility of the Affect smartphone application ("app") as the core component of the Affect digital care program for treatment of methamphetamine use disorder (MUD).

What is the current status of trial NCT05206175?

This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2022-02-14. Estimated completion is 2022-12-31.

What conditions does trial NCT05206175 study?

This clinical trial studies the following conditions: Methamphetamine Abuse.

What interventions are being tested in trial NCT05206175?

The interventions under investigation include: Affect Treatment Program for Methamphetamine Use Disorder (OTHER).

Who is sponsoring clinical trial NCT05206175?

This trial is sponsored by Affect Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05206175 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Methamphetamine Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.